Who is sponsoring NCT00445679?

NCT00445679 is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

What condition does NCT00445679 study?

NCT00445679 studies Depressive Disorder, Major.

What drugs are being tested in NCT00445679?

Interventions: DVS SR, Paroxetine.

What is the status of NCT00445679?

NCT00445679 is currently COMPLETED.

Last reviewed 2013-10-08 · How we verify

A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder

NCT00445679 Phase 3 COMPLETED Results posted

This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.

Details

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	Phase 3
Status	COMPLETED
Enrolment	807
Start date	2007-07
Completion	2009-02

Conditions

Depressive Disorder, Major

Interventions

DVS SR
Paroxetine

Primary outcomes

Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17) — 8 weeks
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.

Countries

China, India, South Korea, Taiwan